Clinical Trial Update: Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating moderate-dose hydroxyurea for secondary stroke prevention in children with sickle cell disease in Sub-Saharan Africa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Stroke

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Status: COMPLETED